- Home
- ADIL vs INM Comparison
ADIL vs INM Comparison
Compare ADIL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | INM |
|---|---|---|
| Founded | 2010 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.7M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADIL | INM |
|---|---|---|
| Price | $4.99 | $1.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | 61.8K | ★ 806.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,942,633.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.13 | $0.58 |
| 52 Week High | $5.17 | $2.50 |
Technical Indicators
Market Signals| Indicator | ADIL | INM |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 50.01 |
| Support Level | $2.38 | $1.45 |
| Resistance Level | $5.08 | $1.52 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 75.79 | 42.67 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.